HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid


JInvestDermatol136_2201_suppl.pdfSupplementary Materials776.48 kBPDF見る/開く
JInvestDermatol136_2201.pdf1.51 MBPDF見る/開く

タイトル: Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid
その他のタイトル: Autoantibody profile differentiates between inflammatory and non-inflammatory bullous pemphigoid
Autoantibody profile differentiates BP phenotypes
著者: Izumi, Kentaro 著作を一覧する
Nishie, Wataru 著作を一覧する
Mai, Yosuke 著作を一覧する
Wada, Mayumi 著作を一覧する
Natsuga, Ken 著作を一覧する
Ujiie, Hideyuki 著作を一覧する
Iwata, Hiroaki 著作を一覧する
Yamagami, Jun 著作を一覧する
Shimizu, Hiroshi 著作を一覧する
キーワード: autoantibody
bullous pemphigoid
collagen XVII
dipeptidyl peptidase-IV inhibitors
発行日: 2016年11月
出版者: Elsevier
誌名: Journal of investigative dermatology
巻: 136
号: 11
開始ページ: 2201
終了ページ: 2210
出版社 DOI: 10.1016/j.jid.2016.06.622
抄録: Bullous pemphigoid (BP) is a major autoimmune blistering skin disorder, in which a majority of the autoantibodies (autoAbs) target the juxtamembranous extracellular noncollagenous 16A domain (NC16A) domain of hemidesmosomal collagen XVII. BP-autoAbs may target regions of collagen XVII other than the NC16A domain; however, correlations between epitopes of BP-autoAbs and clinical features have not been fully elucidated. To address correlations between the clinical features and specific epitopes of BP-autoAbs, we evaluated the epitope profiles of BP-autoAbs in 121 patients. A total of 87 patients showed a typical inflammatory phenotype with erythema and autoAbs targeting the anti-NC16A domain, whereas 14 patients showed a distinct noninflammatory phenotype, in which autoAbs specifically targeted the midportion of collagen XVII, but not NC16A. Interestingly, this group clinically showed significantly reduced erythema associated with scant lesional infiltration of eosinophils. Surprisingly, 7 of the 14 cases (50.0%) received dipeptidyl peptidase-IV inhibitors for the treatment of diabetes. Dipeptidyl peptidase-IV inhibitors were used in 3 of 76 (3.9%) typical cases of BP with autoAbs targeting NC16A; thus, dipeptidyl peptidase-IV inhibitors are thought to be involved in the development of atypical noninflammatory BP. This study shows that the autoAb profile differentiates between inflammatory and noninflammatory BP, and that noninflammatory BP may be associated with dipeptidyl peptidase-IV inhibitors.
Rights: © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
Relation (URI):
資料タイプ: article (author version)
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 泉 健太郎


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学